Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06161415 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study

A Phase 1 study of Inflammation and Uveitis, sponsored by Quan Dong Nguyen.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT06161415 is a Phase 1 study of Inflammation and Uveitis that is actively recruiting participants, run by Quan Dong Nguyen. The registered enrollment target is 12 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06161415, a Phase 1 study of Inflammation and Uveitis, is actively recruiting participants, sponsored by Quan Dong Nguyen.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.

Conditions Studied

Interventions

  • DRUG Laquinimod eye drops

Study Locations (1)

California

  • Spencer Center for Vision Research at the Byers Eye Institute - Palo Alto

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2024-05-03
Est. Completion 2025-07
Phase Phase 1

Sponsor

Quan Dong Nguyen

4 total trials

What the Registry Record Tells You About NCT06161415

The ClinicalTrials.gov registry entry for NCT06161415 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (96% lower). The listed sponsor is Quan Dong Nguyen, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Laquinimod eye drops is the first listed.

NCT06161415 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06161415 about?

NCT06161415 is a clinical study titled "Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study". The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.

What is the current status of trial NCT06161415?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-05-03. Estimated completion is 2025-07.

What conditions does trial NCT06161415 study?

This clinical trial studies the following conditions: Inflammation, Uveitis.

What interventions are being tested in trial NCT06161415?

The interventions under investigation include: Laquinimod eye drops (DRUG).

Who is sponsoring clinical trial NCT06161415?

This trial is sponsored by Quan Dong Nguyen, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06161415 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.